ADC Therapeutics SA
MOLECULAR ADJUVANT
Last updated:
Abstract:
The present disclosure relates to therapies for the treatment of a disorders characterized by a disorder-associated antigen (DAA); vaccination methods are disclosed. In particular, the disclosure describes anti-CD25 ADC molecular adjuvants for use in inducing or enhancing a subject's immune response against a DAA, allowing for treatment of the disorder characterized by the DAA. Also disclosed are dosage regiments for the treatment of solid tumours with an AThe present disclosure relates to the treatment of pathological conditions, such as cancer, with anti-CD25 ADCs.
Status:
Application
Type:
Utility
Filling date:
22 May 2019
Issue date:
14 Apr 2022